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Abstract
The anti–epidermal growth factor receptor antibody cetuximab (Erbitux, CTX) is currently used for the treatment of locally
advanced squamous cell carcinoma of the head and neck (LA-SCCHN), as yet with modest effectiveness, prompting for the
identification of response predictors to this treatment and for the targeting of additional pathways implicated in this disease.
Within this scope, we investigated the effect of SRC/STAT pathway components on LA-SCCHN patient outcome. SRC,
STAT1, STAT3, STAT5A, STAT5B, ANXA1, CAV1, IGFBP2, EPHA2, EPHB2, andMSN relative gene expression, as well as Stat
protein activation, were assessed on LA-SCCHN tumor tissues from 35 patients treated with combined radiotherapy (RT)
and CTX-based regimens. Stat1, Stat3, and Stat5 proteins were usually found activated in neoplastic nuclei (70.4%, 85.7%,
and 70.8%, respectively). Activated Stat3 and Stat5were associatedwith each other (P= .017) andwith aCAV1high/MSNhigh/
IGFBP2low profile. All patients with tumors expressing high STAT5A/EPHA2 experienced a complete response on RT-CTX–
based treatments (12/15 complete responders, P < .0001) and a longer progression-free survival (P = .024). Few tumors
expressed high ANXA1/CAV1/EPHA2 and low IGFBP2, a putative dasatinib response–related profile, whereas high ANXA1
was associated with shorter overall survival (P= .003). In conclusion, Stat activation is common in LA-SCCHN, where over-
expression of STAT5A and EPHA2 may predict for response to RT-CTX treatments. The STAT5A/EPHA2 profile seems of
particular interest for validation in larger cohorts and in multiple tumor types because markers for the positive selection
of patients to benefit from CTX-containing treatments are currently lacking.
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Introduction
Squamous cell carcinoma of the head and neck (SCCHN) is a disease
potentially curable with surgery and radiotherapy (RT) alone when
diagnosed at early stages, as is the case for approximately one-third of
patients. When diagnosed at advanced stages, however, SCCHN has
a high risk for locoregional recurrence and metastasis on surgery and
RT or tumors may be nonresectable. Treatment options for patients
with locally advanced SCCHN (LA-SCCHN) include RTwith con-
comitant administration of cisplatin or cetuximab ([CTX], Erbitux),
a monoclonal antibody that blocks epidermal growth factor receptor
(EGFR) activation, or both [1,2]. CTX in combination with RT has
received US Food and Drug Administration approval for the treat-
ment of patients with LA-SCCHN [3] based on clinical trial results
showing that the drug reduces mortality and may control disease in
collectively 50% of the cases [4], whereas it may also be effective
in patients with recurrent and/or metastatic SCCHN who fail on
platinum therapy [5]. EGFR targeting represents a successful proof-
of-concept paradigm regarding the tumorigenic contribution of this
receptor in SCCHN, as established in both clinical and experimental
settings [6,7]. However, EGFR targeting still remains inefficient for
a large proportion of SCCHN patients. Hence, resolving the mech-
anisms of intrinsic and acquired resistance to CTX in this type of tu-
mors and identifying predictors of response to this drug are largely
needed [7,8].
EGFR signaling is accomplished through three main pathways
(RAS-MAPK, PI3K-AKT, and SRC-STAT), all of which function ab-
errantly in most carcinomas mostly on a ground of genetic alterations
(mutations, gene amplifications/deletions) in the member molecules.
In colorectal and non–small cell lung cancers (NSCLCs), EGFR-
activating mutations are associated with response, whereas KRAS
and BRAF mutations are associated with resistance to therapeutic
EGFR antibodies and kinase inhibitors [9–11]. SCCHNs, however,
do not in general carry KRAS and BRAF mutations [12] or classic
activating EGFR mutations. Further, although the AKT pathway is
usually activated in SCCHN [13], there are as yet no solid data to
associate this parameter with disease outcome or treatment response.
The third signaling pathway downstream of EGFR seems of partic-
ular interest in understanding tumorigenesis and response to anti-
EGFR treatments in several carcinoma models. Three of the seven
known signal transducers and activators of transcription (STATs)
have mostly been studied in SCCHNs, namely, STAT1, STAT3, as
well as STAT5A and STAT5B, which are genes closely neighbored to
each other and to STAT3. STATs are transcription factors that may
play oncogenic roles in the development of SCCHN [14], where Stat
proteins may be activated by EGFR and/or SRC [15] or by non-
EGFR pathways [16]. STATs act through receptor tyrosine kinases
or cytokines [14], whereas their effects on gene transcription and cell
function are described as distinct and nonredundant [17,18].
SRC family kinases (v-src sarcoma (Schmidt-Ruppin A-2) viral onco-
gene homolog, SFKs) and STATs have been associated with resistance
to pharmaceutical EGFR targeting in SCCHN. In SCCHN cells in
culture, a forced expression of dominant-mutant STAT5 conferred
resistance to erlotinib, a small-molecule EGFR inhibitor [19]. Further,
elevated levels of active EGFR, MAPK, AKT/PKB, and STAT3 were
observed in a model of acquired resistance to CTX, whereas STAT3
was found activated in resistant but not in the parental CTX-sensitive
cells [20]. In the same line, SFKs were overactivated in CTX-resistant
NSCLC cells and could be blocked by the Src inhibitor dasatinib [21].
SCCHN cell lines also have overactivated SFKs, STAT3, and STAT5
and can be growth-inhibited by dasatinib [22]. The commonly ob-
served activation of the SRC/STAT pathway in experimental systems
of SCCHN, especially in relevance to CTX resistance, has served as
the rationale for proposing the clinical testing of Src inhibitors in these
tumors [6,8].
Dasatinib (BMS-354825) has been developed as a specific Src/Abl
inhibitor [23] and is currently in clinical use in imatinib-resistant,
Philadelphia chromosome–positive leukemias [24,25], whereas it is also
being tested in phase 1 and 2 studies in solid tumors [26,27]. In an at-
tempt to predict for response to this drug, profiling of dasatinib-resistant
and dasatinib-sensitive cell lines has been undertaken and dasatinib-
response gene expression signatures have been described [28,29]. These
signatures include Src-inducing and target proteins like the highly
homologous closely neighbored caveolins (CAV1 and CAV2), annexin
1A (ANXA1), the ephrin receptors A2 and B2 (EPHA2 and EPHB2),
moesin (MSN ), insulin growth factor binding protein 2 (IGFBP2), and
others. An expression signature of low IGFBP2 and high ANXA1,
CAV1, and EPHA2 would predict sensitivity to dasatinib.
On the basis of the previously mentioned data, we investigated the
effect of SRC/STAT–related gene expression and protein activation in
LA-SCCHN tissues on patient outcome and response to CTX-based
treatments. We also assessed the previously described dasatinib sensitiv-
ity profile because these patients might be candidates for receiving
SRC inhibitors on failure of CTX in the near future. STAT1, STAT3,
and STAT5 were expressed, and the proteins were activated in most
LA-SCCHN, whereas the dasatinib-response–predicting profile was
encountered in few tumors. The most interesting finding of this study
was that complete response to CTX was associated with high STAT5A/
EPHA2 messenger RNA (mRNA) expression in tumor tissues. If vali-
dated in larger cohorts, this profile may prove useful as a positive pre-
dictor for response to anti-EGFR antibodies not only in LA-SCCHN
but also in other tumors where currently negative predictors are used for
the exclusion of patients to receive this type of treatment.
Patients and Methods
A retrospective review of the medical records of 36 patients with newly
diagnosed and histologically confirmed nonnasopharyngeal LA-
SCCHN was undertaken. Twenty-three patients had been treated with
concomitant chemoradiotherapy (CCRT) in five centers. Details about
patient dose modifications, follow-up, and RT technique have been re-
ported previously [30]. Further, 13 patients had been treated with CTX
and RTonly (CTX-RT). All adverse events were graded for this analy-
sis according to the National Cancer Institute Common Terminology
Criteria (version 3.0). TheRadiationTherapyOncologyGroup’s criteria
were used to assess RT-related toxicities.
After a median follow-up of 24.5 months, 11 deaths and 13 pro-
gressions were reported. Median survival has not yet been reached,
but 1-year survival rate was 68%. Response to treatment was evaluated
according to the RECIST criteria, as described in Fountzilas et al. [30].
Selected patient and tumor characteristics are shown in Table 1.
Tissues and Processing
Formalin-fixed paraffin-embedded tumor tissue from 36 patients
was used for protein and gene analysis. Hematoxylin and eosin–stained
sections were assessed by two pathologists for tumor tissue adequacy
and were marked for tissue microarray (TMA) construction and for
macrodissection where necessary (cases with <70% neoplastic cells).
TMAs (two cores per case, 1.5 mm in diameter) were constructed with
a manual arrayer (Beecher Instruments, Sun Prairie, WI).
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Expression Profiling
RNA was extracted from whole or macrodissected formalin-fixed
paraffin-embedded sections by using an experimental method based
on proprietary magnetic beads from Siemens Healthcare Diagnostics
(Cologne,Germany), as previously described [31]. Themethod involves
DNase I treatment for the degradation of contaminating DNA. Reverse
transcription was accomplished with random hexamers and Superscript
III followed by excess RNA removal with RNase H (Invitrogen, Paisley,
UK), according to the instructions of the manufacturer. Exon spanning
TaqMan MGB assays (premade; Applied Biosystems, Biosolutions,
Athens, Greece) were used to assess the relative expression of 12 genes
in comparison to a housekeeping gene (β-glucuronidase [GUSB]). Tar-
get transcripts and assays are shown in Table 2. Except for the genes
mentioned already, PIAS3 (protein inhibitor of activated STAT 3) was
included in the target transcript panel because its low expression or ab-
sence had been reported in association with Stat3 activation in gliomas
[32]. Samples were assessed twice in 20-μl reactions in separate runs
along with no-template controls for 40 cycles under standard conditions
in an ABI7500 real-time polymerase chain reaction (PCR) system and
analyzedwith the SDSv1.4 software (Applied Biosystems, Biosolutions)
by keeping the reading threshold at 0.2 for all evaluations. Criteria for
considering samples eligible for analysis were as follows: 1) for the iden-
tification of minimal quantities of amplifiable complementary DNA:
GUSB CT values <36 and 2) for the evaluation of sample adequacy
and PCR efficiency in consecutive runs: absolute difference of ΔCT
(CTtarget − CTGUSB) values for the same sample was less than 0.5. By
using these criteria, 31 of 36 samples were found eligible for further
analysis. Relative expression of the target transcripts was assessed as
the 2−ΔCT value (relative quantification value [RQ]) based on equal
PCR efficiency for very short amplicons [33]. Mean RQs for each eli-
gible sample were used for analysis.
Immunohistochemistry
Activation of Stat1, Stat3, Stat5, and AKT/PKB was assessed with
antibodies against phosphorylated sites in the corresponding proteins.
TMA sections were incubated with monoclonal antibodies (Cell Signal-
ing, Boston, MA) diluted 1:50 against Stat1-phospho-Tyr701, clone
58D6 (Stat1), Stat3-phospho-Tyr705, clone D3A7 (Stat3), Stat5-
phospho- Tyr694, clone C11C5 (Stat5), AKT-phospho-Thr308, clone
244F9H2 (Akt-T308), and AKT-phospho-Ser473, clone 736E11 (Akt-
S473). Antigen epitopes were retrieved with a citrate mixture, pH 6.2
to 4, whereas the Envision system and diaminobenzidine were used for
visualizing the antibody-antigen complex (all reagents from DAKO,
Glostrup, Denmark).
Immunohistochemistry (IHC) markers were evaluated as negative
and positive by using a 5% positivity cutoff. Tumors were characterized
as positive for activated Stat1, Stat3, and Stat5 when they exhibited
greater than 5% positive nuclei; as positive for phosphorylated Akt-
T308, when greater than 5% cytoplasmic staining was observed; and
as positive for phosphorylated Akt-S473, when greater than 5% of cells
exhibited cytoplasmic and/or nuclear staining (scoring modified from
Mizoguchi et al. [34] and Yamashita et al. [35]).
Table 1. Selected LA-SCCHN Patient and Tumor Characteristics.
N = 36 CCRT
(n = 23)
CTX-RT
(n = 13)
Age, years
Median (range) 64 (40-82) 65 (40-82) 60 (40-81)
n % n % n %
<60 16 44 12 33 4 11
≥60 20 56 11 31 9 25
Sex
Man 30 83 18 50 12 33
Woman 6 17 5 14 1 3
Alcohol
No 15 42 10 28 5 14
Yes 21 58 13 36 8 22
Smoking
No 13 36 12 33 1 3
Yes 23 64 11 31 12 33
Performance status
0 31 86 19 53 12 33
1 4 11 3 8 1 3
2 1 3 1 3 — —
Primary tumor location
Oropharynx 7 19 5 14 2 6
Hypopharynx 2 6 2 6 — —
Larynx 15 42 6 17 9 25
Oral cavity 10 28 9 25 1 3
Paranasal sinuses 2 6 1 3 1 3
Histology grade
Well differentiated 1 3 1 3 — —
Moderately differentiated 10 28 5 14 5 14
Poorly differentiated 22 61 15 42 7 19
Undifferentiated 1 3 — — 1 3
Unknown 2 6 2 6 — —
Stage
II 1 3 — — 1 3
II 5 14 4 11 1 3
IVA 28 78 17 47 11 31
IVB 1 3 1 3 — —
Unknown 1 3 1 3 — —
Table 2. Target Transcripts That Have Been Assessed for Relative Expression with FAM-TaqMan-MGB Assays.
Target Transcript Chromosomal Location Assay ID RNA Reference (GenBank) Position Amplicon Length (bp)
SRC 20q12-q13 Hs00178494_m1 NM_198291.1, NM_005417.3 ex 7-8 70
STAT1 2q32.2 Hs01014005_m1 NM_139266.2, NM_007315.3 ex 3-4 67
STAT3 17q21.31 Hs01047580_m1 NM_213662.1, NM_139276.2, NM_003150.3 ex 3-4 87
STAT5A 17q11.2 Hs00234181_m1 L41142.1 ex 11-12 63
STAT5B 17q11.2 Hs00560035_m1 NM_012448.3 ex 2-3 91
PIAS3 1q21 Hs00180666_m1 NM_006099.3 ex 7-8 102
ANXA1 9q12-q21.2 Hs00167549_m1 NM_000700.1 ex 8-9 66
CAV1 7q31.1 Hs00971716_m1 NM_001753.3 ex 2-3 66
EPHA2 1p36 Hs00171656_m1 NM_004431.2 ex 16-17 55
EPHB2 1p36.1-p35 Hs00362096_m1 NM_017449.3, NM_004442.6 ex 3-4 67
ex 3-4 67
IGFBP2 2q33-q34 Hs00167151_m1 NM_000597.2 ex 1-2 70
MSN Xq11.2-q12 Hs01085677_g1 NM_002444.2 ex 10-11 61
GUSB (reference transcript) 7q21.11 4333767 NM_000181.1 ex 11-12 81
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Statistics
One of the major problems and challenges in studies dealing with
relative gene expression is the reference system against which the ob-
tained results are compared and analyzed. In this case, SCCHNs arise
in a variety of epithelia with different functional properties, whichmakes
it impossible to obtain one adequate reference tissue system for relative
expression analysis. Ideally, normal counterparts of all tumors should be
available for analysis, but this is practically not possible. Further, the
commonly used pooled “normal” cell line template was considered in-
appropriate as well because transformation is required for normal epithe-
lial cells to grow in culture, which per se abrogates normal control of
survival and proliferation pathways. Hence, in this study, we considered
it more pragmatic to analyze tumor samples only.
Categorical data were presented as counts and corresponding percent-
ages, whereas continuous variables were summarized using medians and
ranges. Correlations between the examined genes were calculated with
the Spearman ρ correlation. To approach how high and low expression
of the investigated genes associated with response to treatment, survival
and progression-free survival (PFS), we used the extreme (upper and
lower) quartile and median RQ values for each transcript target.
Comparisons between gene expression and clinicopathologic charac-
teristics, as well as response to treatment were performed by using the
χ2 and Fisher exact test where appropriate. The Mann-Whitney test
was performed to compare the distribution of each transcript target ac-
cording to the status (positive/negative) of each IHC marker.
Survival was measured from treatment initiation until death from
any cause or date of last contact. PFS was measured from the time of
treatment initiation to verified disease progression, death, or last contact.
Both survival and PFSwere estimated using the Kaplan-Meier product–
limit method and comparisons were performed using the log-rank test.
To estimate the hazard ratios of gene expression and protein activa-
tion data for survival and PFS, univariate Cox regression analyses were
performed. Hazard ratios are presented along with the corresponding
P values from the Wald test. Follow-up was last updated in March
2010. All tests were two-sided, and the level of significance was set
at α = 0.05. Analysis was conducted by using the SPPS software for
Windows, version 15 (SPSS Inc, Chicago, IL).
Results
SRC and SRC-Related Gene Expression in LA-SCCHNs
Relative expression results are shown in Table 3 and Figure 1. mRNA
expression of SRC, STAT1, STAT3, and STAT5A, as well as of genes
coding for proteins that are functionally related to Src and blocked
by Src inhibitors, such as ANXA1, CAV1, EPHA2, and IGFBP2, was
detectable in considerable although variable ratios versus GUSB in all
LA-SCCHN samples eligible for relative quantification analysis (n =
31). In comparison, some of these tumors expressed very low to un-
detectable levels of PIAS3, a STAT3 inhibitor (n = 3); of STAT5B,
the second STAT5 component (n = 3); of EPHB2, a receptor for
ephrin-B family members (n = 1); and ofMSN (moesin), a cytoskeleton
stabilizer (n = 6). Among all STATmembers, STAT1 was found to be
expressed in relatively higher levels versus GUSB, whereas most LA-
SCCHNs (20/31 [64.5%]) expressed ANXA1 >15-fold than this
housekeeping gene.
STAT3 was expressed in parallel with STAT5B (P = .0019), which
might suggest common regulatory events for these two neighbored
genes that are located on the same strand at 17q21. By contrast, STA-
T5A, which is located between STAT3 and STAT5B but on the comple-
mentary strand, was expressed independently of these two genes and
correlated with SRC expression (P = .0024). Thus, the two STAT5 genes
did not seem to share common activators in LA-SCCHN.
ANXA1 and EPHA2 expression also correlated strongly with each
other (P < .0001) but not with SRC or any STAT gene tested, providing
evidence for separate transcription regulation of ANXA1/EPHA2 and
SRC/STAT genes in LA-SCCHN.
MSN expression varied in parallel with CAV1 (P < .0001) and
EPHB2 (P = .0191). MSN mRNA also correlated with the expression
of STAT family members, namely, with STAT3 (P = .0020) and less
with STAT5B (P = .0302) transcript levels. PIAS3 expression was posi-
tively related to STAT3 (P = .0166), whereas it was also strongly related
toMSN (P < .0001) and toCAV1 (P = .0081). In all, themost significant
above bivariate correlations suggest that 1) the negative regulatory loop
for STAT3 inhibition through PIAS3 might be functional in LA-
SCCHN, unlike to what seems to be the case in glioblastomas [32];
2) transcription ofMSN, STAT3, and its inhibitor PIAS3 may be regu-
lated by common signaling; 3) transcriptional activation of CAV1 and
SRC/STAT genes are not interrelated.
STAT1 and IGFBP2 expression did not correlate with any other mRNA
target tested here. No significant negative correlations were observed.
Activation of Stat and Akt/PkB Proteins in LA-SCCHNs
The three Stat proteins investigated in this study were found acti-
vated (phosphorylated) in most LA-SCCHN tumors, as indicated by
the specific nuclear staining for each target (Figure 2, A–C ). Stat3 phos-
phorylation was the most frequent event, usually coinciding with Stat5
phosphorylation (Fisher exact test, P = .017). Stat1-positive cells were
usually confined to the most differentiated areas of the tumor (Fig-
ure 2A). No significant association was observed between each one of
these activated proteins with the clinical and histopathologic parameters
presented in Table 1. Activation of these proteins, as assessed by IHC,
was not related to the level of the corresponding mRNA expression.
Table 3. mRNA Expression Characteristics of All Genes Examined: Relative Quantification* Was Performed for Individual LA-SCCHN Tumors.
SRC STAT1 STAT3 STAT5A STAT5B PIAS3 ANXA1 CAV1 EPHA2 EPHB2 IGFBP2 MSN
Mean 1.1390 7.9610 2.1000 0.2745 0.1265 0.1153 24.5500 0.5973 0.9563 0.2101 2.1290 0.3232
SD 1.0540 6.8930 1.0680 0.2478 0.0841 0.1298 32.1900 0.8089 0.8034 0.2182 3.0930 0.3181
SE 0.1862 1.2190 0.1889 0.0438 0.0149 0.0230 5.6910 0.1430 0.1420 0.0386 0.5468 0.0562
Minimum 0.0699 0.5404 0.4121 0.0217 0.0001 0.0001 1.1240 0.0260 0.0513 0.0001 0.0475 0.0001
Maximum 5.8320 30.5500 4.8200 1.4790 0.3169 0.5141 183.8000 2.7740 2.9340 0.9526 11.9700 1.2300
25th percentile 0.5222 2.9450 1.3240 0.1465 0.0588 0.0284 7.1690 0.0830 0.3876 0.0764 0.3324 0.0943
Median 0.9758 7.0570 1.8700 0.2106 0.1202 0.0702 16.0100 0.2045 0.6922 0.1369 0.7533 0.2153
75th percentile 1.3820 10.1400 2.5760 0.3306 0.1956 0.1608 31.6900 0.9123 1.2230 0.2235 2.4610 0.5378
*Values were calculated with the 2−ΔCT method for target versus GUSB, where ΔCT = (CTtarget) − (CTGUSB).
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Discordance between mRNA and protein expression for STAT3 and
STAT5A has previously been reported [36,37], whereas activation of
Stat proteins in SCCHN is induced by a number of signal transduc-
tion pathways that do not always depend on STATmRNA expression
(recently reviewed in Lai and Johnson [38]). Interestingly, however,
tumors positive for Stat5 phosphorylation expressed relatively high
CAV1 andMSN but relatively low IGFBP2 mRNA (Figure 3). Results
in the same line were also obtained for Stat3 phosphorylation; how-
ever, because of the very small number of cases without activated
Stat3, comparisons between positive and negative cases for this marker
Figure 1. Relative expression of STAT and SRC-related genes in LA-SCCHN. The distribution of RQ values reflecting the presence of gene
transcripts in comparison to those of GUSB (housekeeping gene) is presented in a logarithmic scale. Horizontal lines correspond to
mean values per category; black dots, SRC/STAT genes; gray dots, genes producing SRC target proteins, some of which (box) are in-
cluded in the proposed gene signature predicting for response to dasatinib.
Figure 2. Immunohistochemical investigation of Stat and Akt/PKB activation in LA-SCCHN. Microphotographs A to E (all magnifications,
×200): A typical case of a well-differentiated LA-SCCHN is shown (antibodies as indicated for eachmicrophotograph). Stat1, Stat3, and Stat5
proteins seemactivated, whereas Akt (Akt1-3) proteins are phosphorylated at Thr308 but not at Ser473. This profilewas observed inmost LA-
SCCHN, as collectively shown in the graph in F.Numberswithin bars correspond to the rate of immunopositivity obtainedwith each antibody.
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might represent statistical artifacts and should definitely be validated
in larger studies.
Akt/PKB was frequently found phosphorylated at Thr308 but less
so at Ser473 (Figure 2, D–F). Immunopositive LA-SCCHNs for Akt-
Ser473 showed increased STAT1 mRNA expression in comparison to
Akt-Ser473–negative tumors (Figure 3). In the same line with Stat5 ac-
tivation, tumors with phosphorylated Akt at Thr308 expressed lower
levels of IGFBP2; however, this result was again limited by the very small
number of A4kt-Thr308–negative cases.
STAT and SRC-Related Expression Profiles in Association
with Treatment Response
Patient follow-up data in association with the observed gene expres-
sion profiles are shown in Table 4. LA-SCCHN tumors expressing very
high ANXA1 levels (upper quartile) were associated with significantly
shorter survival (hazard ratio [HR] = 8.03, 95% confidence interval
[CI] = 4.32-11.74, P = .0026) and marginally with earlier relapse of dis-
ease (HR = 6.03, 95%CI = 3.81-8.25, P = .0502; Figure 4). No further
significant association was observed on overall and PFS for any other
parameter tested, including IHC-determined activation of Stat and
Akt proteins.
Of 37 patients, 35 were assessable for response to CTX-based
treatments; 17 (47%) were complete responders, 6 (17%) showed
partial response, 2 (6%) had stable disease, and 10 (28%) developed
progressive disease while treated. Among patients with disease pro-
gression, there was one patient who discontinued treatment because
of grade 3 mucositis and died a few months later. One patient was not
assessable for response because he died early of disseminated disease, and
for the rest, no information for response was available. mRNA profiling
data were obtained in 31 of the above 35 cases (Table 4 and Figure 5A).
All patients with tumors expressing very high levels of STAT5A
and EPHA2mRNA (RQ values in the upper quartile) exhibited a com-
plete response on CTX-based treatments; by contrast, none of the tu-
mors in the group of non–complete responders (0/16) expressed very
high STAT5A and EPHA2 (P = .0002 each; Figure 5A). When assessing
these two genes together at the same RQ value cutoff (upper quartile),
12 of 15 tumors in the complete responder group expressed very high
STAT5A orEPHA2mRNAor both (P < .0001). This expression pattern
was further associated with prolonged PFS for LA-SCCHN patients
(Figure 5B). This significant association of STAT5A and EPHA2 expres-
sion with best response to CTX-based treatment of LA-SCCHN was
not maintained when assessing RQ values at lower cutoffs (median
and lower quartile).
In addition, response to CTX-based treatment was negatively related
to Stat1 protein phosphorylation (P = .009) because all patients bearing
tumors without Stat1 activation were complete or partial responders (n =
8, almost half of the cases in the responders group). However, five of
these tumors expressed very high STAT5A and two very high EPHA2
levels; hence, it is questionable whether the absence of Stat1 activation
contributed to tumor response in these cases.
Because it had been proposed that SRC pathway targeting could be of
benefit for patients with LA-SCCHN, especially those not responding
to CTX treatments [6,21], it seemed rational to investigate whether
the previously described dasatinib response–predictive signature for
solid tumors [28] would be expressed in our cases. Four of the six genes
in this signature were analyzed here (ANXA1, CAV1, EPHA2, and
IGFBP2), and profiles were obtained for all RQ value cutoffs (upper
and lower quartiles, and median [Figure 4B]). Among the 31 patients
Figure 3. Relative expression of CAV1,MSN, IGFBP2, and STAT1 in
association with Stat and Akt protein phosphorylation in LA-SCCHN.
Tumors were categorized as positive/negative for phosphorylated
Stat1-Y701, Stat3-Y705, Stat5-Y694, Akt-T308, and Akt-S473. RQ
values are shown in a logarithmic scale. Horizontal lines correspond
to mean values per category. Categories (IHC status, x axis) in the
lower graph are valid for all graphs. Statistically significant associa-
tions of gene expression with Stat/Akt phosphorylation status are
shown (Mann-Whitney P, exact significance, two-sided).
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with available RNA data (15 complete responders, 16 non–complete
responders), ratios of the four gene transcripts compatible with the de-
scribed dasatinib response signature, i.e., high ANXA1/CAV1/EPHA2 -
low IGFBP2, were obtained 1) for two responders, when assessing RQs
with the upper quartile cutoff; 2) for three responders with the median
cutoff; and 3) in four tumors with the low quartile cutoff. The latter
four tumors corresponded to one complete responder, one patient with
partial response and two patients with progressive disease. Except for
Table 4. Gene Expression in Comparison to LA-SCCHN Patient Outcome and Response to CTX-Containing Treatments.
Sample Treatment Overall
Survival (mo)
Progression Free
Survival (mo)
Response SRC STAT1 STAT3 STAT5A STAT5B PIAS3 ANXA1 CAV1 EPHA2 EPHAB2 IGFBP2 MSN
1 CCRT 31.87* 11.67 CR 433 7.255 2.155 0.215 0.101 0.127 41.098 0.098 1.159 0.369 0.515 0.588
2 CCRT 39.18* 39.18† CR 0.479 5.938 0.412 0.022 0.043 0.001 9.331 0.048 0.329 0.098 0.116 0.000
3 CCRT 23.08* 23.08† CR 0.070 10.346 1.423 0.112 0.000 0.061 29.081 0.110 2.581 0.116 1.197 0.112
4 CCRT 4.33 4.33 CR 1.375 2.377 1.829 0.496 0.042 0.067 2.369 0.906 0.421 0.021 0.323 0.230
5 CCRT 33.34* 33.34† CR 3.301 6.859 4.213 0.448 0.271 0.040 4.938 0.247 0.185 0.225 0.796 0.458
6 CCRT 31.67* 31.67† CR 1.184 17.268 3.848 1.479 0.160 0.043 20.966 0.113 0.602 0.139 0.269 0.115
7 CCRT 4.95 4.95 CR 1.252 2.809 2.556 0.199 0.237 0.107 52.527 0.042 2.757 0.013 0.619 0.091
8 CCRT 36.95* 36.95† CR 0.967 7.738 1.654 0.247 0.071 0.055 33.174 0.068 1.597 0.092 0.304 0.304
9 CCRT 24.33* 24.33† CR 1.154 2.413 2.509 0.389 0.317 0.039 32.111 0.296 2.249 0.073 3.456 0.219
10 CCRT 9.44 9.44 ED 0.376 2.135 2.118 0.114 0.057 0.023 49.351 0.057 0.981 0.182 2.521 0.000
11 CCRT 7.93 3.70 PD 1.402 7.408 2.439 0.126 0.064 0.137 3.031 0.357 0.550 0.586 2.280 0.580
12 CCRT 6.30 3.93 PD 5.832 5.808 2.583 0.291 0.103 0.000 37.453 0.078 0.787 0.000 0.649 0.000
13 CCRT 24.49* 4.13 PD 1.138 8.369 1.376 0.309 0.113 0.022 31.341 0.184 0.633 0.166 0.173 0.201
14 CCRT 26.62* 4.16 PD 1.456 3.613 1.253 0.316 0.000 0.000 24.218 0.104 0.912 0.013 0.279 0.000
15 CCRT 10.98 4.85 PD 0.920 4.426 3.665 0.335 0.210 0.085 24.251 0.184 0.751 0.012 0.641 0.174
16 CCRT 31.87* 31.87† SD 0.898 30.548 2.918 0.197 0.089 0.213 17.113 1.163 0.826 0.478 0.160 0.837
17 CCRT 25.93* 25.93† CR 0.119 7.749 0.962 0.211 0.139 0.074 14.591 0.149 0.868 0.075 0.711 0.275
18 CCRT 23.87* 23.87† CR 0.535 0.540 1.208 0.201 0.053 0.034 11.259 0.047 0.051 0.074 11.967 0.000
19 CCRT 20.69 11.67 CR 0.274 0.880 0.554 0.146 0.000 0.000 6.945 0.064 0.307 0.220 1.028 0.000
20 CTX-RT 13.38* 13.38† CR 1.385 12.510 1.112 0.286 0.199 0.130 6.974 0.026 0.480 0.099 6.639 0.103
21 CTX-RT 12.85* 12.85† CR 0.700 5.007 1.487 0.390 0.251 0.026 13.251 0.191 0.335 0.081 0.405 0.118
22 CTX-RT 12.79* 12.79† CR 1.456 27.819 1.729 0.404 0.127 169 22.362 1.813 2.385 0.453 0.430 0.540
23 CTX-RT 4.16* 4.16† CR 1.173 8.468 2.136 0.149 0.107 0.079 31.801 2.498 1.485 0.181 1.489 0.617
24 CTX-RT 16.36* 16.36† CR 0.518 3.352 2.045 0.210 0.185 0.514 9.626 1.405 0.583 0.117 3.297 0.267
25 CTX-RT 4.43* 4.43† CR 1.410 1.619 3.880 0.192 0.212 0.412 83.801 2.693 2.934 0.953 5.318 0.703
26 CTX-RT 9.51 8.95 PD 0.984 8.185 4.820 0.185 0.178 0.375 1.124 0.217 0.378 0.595 6.316 1.230
27 CTX-RT 6.1* 3.80 PD 0.726 9.540 1876 0.190 0.151 0.176 4.817 0.262 0.511 0.146 0.360 0.412
28 CTX-RT 8.03 6.03 PD 1.967 11.951 1.863 0.286 0.159 0.073 25.142 2.774 1.244 0.138 1.215 0.532
29 CTX-RT 9.28* 9.28† PR 0.469 12.790 0.832 0.130 0.082 0.062 6.807 0.586 0.418 0.216 0.047 0.513
30 CTX-RT 7.9* 7.9† PR 1.068 4.132 2.592 0.120 0.200 0.340 12.034 1.100 0.874 0.136 1.785 1.021
31 CTX-RT 5.05* 5.05† PR 0.611 2.063 1.307 0.047 0.128 0.205 14.908 0.320 0.193 0.102 11.737 0.162
Relative quantification values were calculated with the 2−ΔCT method for target versus GUSB.
CCRT indicates concomitant chemoradiotherapy; CR, complete response; CTX-RT, cetuximab + radiotherapy; ED, early death; mo, months; PD, progressive disease; PR, partial response; SD, stable disease.
*Patients still alive.
†Patients without events during the follow-up period.
Figure 4. Association of low ANXA1 expression with favorable LA-SCCHN patient outcome. Although relative ANXA1 expression was only
marginally related to progression free survival (PFS, shown in A), low ANXA1 RQ values were observed in tumors from patients with longer
overall survival (B) (HR = 8.03, 95% CI = 4.32-11.74).
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one tumor that was identified as positive for this dasatinib response
predictive signature with both the upper quartile and median cutoffs,
all other tumors positive for this signature did not overlap among the
three different cutoff result groups.
Discussion
This study shows that LA-SCCHN may express high levels of SRC,
STAT1, STAT3, and STAT5A transcripts and that most of these tumors
exhibit activated Stat1, Stat3, and Stat5 proteins. It seems that STAT3
and STAT5 are functionally more closely related to each other than to
STAT1, perhaps in accordance with previous reports showing that
STAT1 plays different roles than STAT3 in SCCHN [39], where STAT1
may function as a tumor suppressor and may be silenced [40]. Indeed,
activated Stat1 was present in the best differentiated parts of the tumor,
which might support a protective effect of this protein versus tumor pro-
gression [40,41]. However, STAT1 expression was the highest among
all STATs examined, indicating that this gene is not silenced in SCCHN,
in accordance with another previous report [42].
Figure 5. STAT/SRC–relatedmRNA expression profiles were associated with response to treatment in LA-SCCHN. In A, a high expression of
STAT5A and/orEPHA2was associatedwith complete response to CTX-based treatments.Most tumors frompatientswho performed best on
CTX-based treatments (12/15 [80%]) expressed high levels of STAT5A and/or high levels of EPHA2 (P< .0001; odds ratio = 58.67; 95%CI =
5.4–64.5; positive predictive value = 1, negative predictive value = 0.8) as assessed by using the upper RQ value quartile (75% percentile).
This high STAT5A/EPHA2 pattern was further associated with prolonged PFS (HR = 9.44, 95% CI = 6.48-12.40) but not with patient overall
survival, as shown in B. In C, the proposed dasatinib response–predictive signature with high ANXA1/CAV1/EPHA2 and low IGFBP2 was
seldom encountered in LA-SCCHN (red dots). Cases are listed in the same order in the three panels. According to the definition of high
and low (upper quartile, median, and lower quartile cutoffs for RQ values), different tumors seemed positive for this profile, some of which
responded completely to CTX-based treatments. Panels in A and C: ▪ = high; □ = low RQ values.
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Overall, none of the STATmarkers (mRNA or activated protein) was
associated with disease outcome in our series; yet, activated Stat3 and
Stat5 proteins were associated with CAV1, MSN, and IGFBP2 mRNA
expression in LA-SCCHN. Although the number of cases examined
in this study was small and the data obtained need validation in larger
studies, the association of activated Stat5 with CAV1, MSN, and
IGFBP2 expression is of interest especially because all these molecules
represent SRC signaling targets, whereas SRC and STAT5A mRNA ex-
pression correlated significantly with each other. Caveolins participate
in the function of the caveolae, structures involved in the internalization
of inactive signaling molecules. CAV1 is generally considered as a tumor
suppressor [43] and may play an antimetastatic role in SCCHN; its
absence or low expression is associated with metastatic growth, whereas
its restoration induces growth arrest and prevents metastatic spread of
SCCHN cells in animal models [44]. Msn, a cytoskeletal protein, de-
creases with progression of carcinogenesis in the squamous oral cancer
model [45], whereas another member of the same protein family, ezrin,
has been associated with worse prognosis in SCCHN [46]. Decreased
MSN expression [45] and altered subcellular localization [47] are also
associated with increased metastatic potential of oral squamous cell tu-
mors. Hence, CAV1 and MSN may be regarded as tumor suppressors
in SCCHN. In comparison, IGFBP2 is usually regarded as an oncogene
with a well-established role in promoting tumor growth and metastasis
in various types of cancers [48–54], whereas IGFBP2 mRNA and pro-
tein expression have been associated with unfavorable tumor charac-
teristics [55,56]. In addition, IGFBP2 regulates IGF binding to and
activation of IGF1R, which is implicated in resistance to CTX and is
considered as a therapeutic target in SCCHN [57]. On the basis of
these data, because Stat3 and Stat5 phosphorylation was mostly ob-
served in tumors with high CAV1 and MSN but low IGFBP2 expres-
sion, it does not seem likely that activation of these two proteins occurs
in the tumor-promoting setting in LA-SCCHN. In line with this view,
constitutive activation of Stat3 and Stat5 in nasopharyngeal carcinomas
correlates with better prognosis [58]. In addition, when both Stat3 and
Stat5 are activated in breast cancer cells, they are also associated with
favorable prognostic parameters, such as decreased proliferation and in-
creased chemosensitivity to taxanes and vinorelbine [59]. Individually,
Stat5 protein expression has been described as a favorable prognostic
factor in breast cancer [35], whereas nuclear Stat3 protein expression
seems associated with a favorable outcome in SCCHNs [60]. The
above evidence along with the data from this study indicates that the
effect of Stat3 and Stat5 activation in SCCHN development, mainte-
nance, and clinical/pharmacological behavior may be different in tissues
than in cell culture systems.
Activated Stat3 and Stat5 were not related to CTX-containing treat-
ment response in our series. This finding may seem as contrasting to the
previously reported experimental evidence on the role of these Stat pro-
teins in promoting resistance to EGFR-inhibiting agents [19,20]. An
explanation for this discrepancymight be that Statsmay also be activated
in an EGFR-independent paracrine manner in SCCHN [16], which
may well be the case at the tissue level. As shown herein, LA-SCCHN
expressing the highest levels of STAT5A mRNA responded best to
CTX-based treatments in this study, whereas SCCHNs were found to
express low to very low levels of STAT5B. With the IHC antibody avail-
able to assess Stat5 phosphorylation, it is impossible to distinguish
whether Stat5a or Stat5b or both are phosphorylated in tissue sections;
hence, the activation status of each one of these two proteins in our LA-
SCCHN series remains unknown. Our finding on the association of
STAT5A expression with CTX response may be related to the different
actions of the two Stat5 components reported in several systems includ-
ing SCCHN: Stat5a does not promote SCCHNgrowth, whereas Stat5b
does [61,62], prompting for a distinction between these two molecules
in the research setting and in data reporting.
Except for STAT5A, EPHA2 expression was also associated with
best response to CTX-based treatments in our LA-SCCHN. EphA2
is generally considered as a pro-oncogenic molecule, but the function
of this receptor and its ligand ephrinA1 in tumorigenesis and tumor pro-
gression is complex and seems to be dependent on cell type and micro-
environment [63]. EphA2 has been correlated with poor prognosis in
esophageal carcinomas [64], glioblastomas [65], and NSCLC [66],
whereas EphA2 overexpression might be involved in the early develop-
ment of SCCHN [67]. Interestingly, EPHA2 gene transcription may
be upregulated by EGFR in squamous cell carcinoma cell lines because
of EGF activation [68]. At the tissue level, we could observe a statistical
trend for increased EPHA2 expression in LA-SCCHNwith high EGFR
protein score, as assessed by IHC [30] (data not shown). Thus, EPHA2
seems to be an EGFR target gene and may be considered as a surrogate
marker for EGFR activation through EGF, which represents the opti-
mal condition for CTX to exert its growth inhibitory properties [69].
Considering EPHA2 as a marker of EGF/EGFR activation might fur-
ther explain why tumors expressing high levels of EPHA2 respond best
to CTX-based treatments, as reported herein. Clearly, to use mRNA ex-
pression levels and profiles in drug response prediction, solid cutoffs and
reference systems need to be established. As shown here, the STAT5A
and EPHA2 mRNA profile seems promising as a marker predictive of
response to CTX-based treatments in LA-SCCHN, when relative ex-
pression values in the upper quartile are considered (very high expres-
sion). The threshold for “very high expression” remains to be defined in
larger studies with reliable external reference systems.
The same considerations on the evaluation of mRNA profiles apply
to the proposed dasatinib response-predicting signature [28], which was
tested here to identify LA-SCCHN that would probably benefit from
dasatinib treatment on CTX failure. Except for EPHA2 that has been
described as an SRC target in colon carcinogenesis [70] and as a dasatinib
target in breast and prostate cancers [28,29], this profile further involves
ANXA1, three caveolae-related genes, and IGFBP2. As shown here,
according to the applied cutoff for relative expression values (upper/lower
quartiles, median), only 7% to 13% of tumors expressed high ANXA1/
EPHA2/CAV1 and low IGFBP2. Whereas it is not surprising that differ-
ent patients were identified as possibly sensitive to dasatinib according
to how the cutoffs were defined, it should be noted that the predictive
value of this older one or of the new modified dasatinib predictive signa-
tures remains unknown [71].
ANXA1, an inhibitor of phospholipase A2 and anti-inflammatory
protein, is reported as downregulated in most types of cancer [72]
and may serve as a differentiating factor in SCCHN development and
histopathologic status [72–75]. In our series, however, overall survival of
LA-SCCHNpatients was adversely affected by highANXA1 expression,
in line with a recent report on high ANXA1mRNA in association with
poor survival in colon cancer [76], where this molecule was examined in
the frame of inflammatory response in cancer. This unfavorable ANXA1
association was not related to treatment variations (CCRT vsCTX-RT).
Of note, however, all treatment schemes for LA-SCCHN involve local
irradiation, although response to this modality is not evaluated separa-
tely. In this context, ANXA1 has been found upregulated in radiation-
resistant NSCLC cells [77], whereas it may also protect breast cancer
cells from heat-induced growth arrest [78]. Additional preclinical evi-
dence is needed to elucidate whether ANXA1 affects survival of patients
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with LA-SCCHNand possibly other tumors as well, as an inflammatory
molecule or by conferring tumor cell survival advantage on irradiation or
by both mechanisms.
Finally, we observed that Akt/PKB is commonly activated in
SCCHNs, mostly at T308, implying a preferential activation through
the phosphoinositide-3-kinase/pyruvate dehydrogenase kinase (PI3K/
PDK1) pathway than through the mechanistic target of rapamycin
(mTOR) complex [79]. However, other than previously suggested for
prediction of response to EGFR inhibitors [80], no clear association
was observed between Akt phosphorylation and response to CTX-
based treatments.
In summary, this exploratory study provides a global overview of
the effect of STAT and SRC-related parameters in the behavior of
LA-SCCHN. In this respect, activated Stat proteins are frequently ob-
served in LA-SCCHN, but Stat3 and Stat5 activation seems associated
with an antioncogenic gene expression profile. In the same tumors, an
mRNA expression profile involving STAT5A andEPHA2was associated
with complete response to CTX-based treatments. If validated in larger
cohorts and standardized for the evaluation of individual tumors, the
high STAT5A/high EPHA2 profile may be applied for assessing
LA-SCCHNpatient treatment. The same profile might be worth inves-
tigating as a positive marker for predicting response to CTX in tumors
lacking the established negative predictors in this context, namely,
KRAS/BRAF mutations.
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